Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells

BACKGROUND: Patients with triple negative breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumour relapse, due to the resistance to chemotherapy. These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs). Therefore, targeting BCSCs is a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Tian, Jun, Raffa, Fatmah Al, Dai, Meiou, Moamer, Alaa, Khadang, Baharak, Hachim, Ibrahim Y., Bakdounes, Khldoun, Ali, Suhad, Jean-Claude, Bertrand, Lebrun, Jean-Jacques
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6288167/
https://ncbi.nlm.nih.gov/pubmed/30482914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0287-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak